RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes Without the Side Effects of RXR Full Agonists

Overview

Journal ACS Med Chem Lett

Publisher American Chemical Society

Specialty Chemistry

Date 2014 Jun 6

PMID 24900488

Citations 10

Authors

Hiroki Kakuta

Nobumasa Yakushiji

Ryosuke Shinozaki

Fuminori Ohsawa

Shoya Yamada

Yui Ohta

Kohei Kawata

Mariko Nakayama

Manabu Hagaya

Chisa Fujiwara

Makoto Makishima

Shigeyuki Uno

Akihiro Tai

Ami Maehara

Masaru Nakayama

Toshitaka Oohashi

Hiroyuki Yasui

Yutaka Yoshikawa

Affiliations

Soon will be listed here.

Abstract

Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.

Citing Articles

Comparative Evaluation and Profiling of Chemical Tools for the Nuclear Hormone Receptor Family 2.

Lewandowski M, Busch R, Marschner J, Merk D ACS Pharmacol Transl Sci. 2025; .

PMID: 40046426 PMC: 7617459. DOI: 10.1021/acsptsci.4c00719.

Applications of palladium-catalyzed C-N cross-coupling reactions in pharmaceutical compounds.

Emadi R, Bahrami Nekoo A, Molaverdi F, Khorsandi Z, Sheibani R, Sadeghi-Aliabadi H RSC Adv. 2023; 13(27):18715-18733.

PMID: 37346956 PMC: 10280806. DOI: 10.1039/d2ra07412e.

Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN.

Kawasaki M, Motoyama T, Yamada S, Watanabe M, Fujihara M, Kambe A ACS Med Chem Lett. 2023; 14(3):291-296.

PMID: 36923911 PMC: 10009790. DOI: 10.1021/acsmedchemlett.2c00509.

An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.

Jurutka P, Di Martino O, Reshi S, Mallick S, Sausedo M, Moen G Int J Mol Sci. 2022; 23(24).

PMID: 36555852 PMC: 9782500. DOI: 10.3390/ijms232416213.

Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and....

Jurutka P, Di Martino O, Reshi S, Mallick S, Sabir Z, Staniszewski L Int J Mol Sci. 2021; 22(22).

PMID: 34830251 PMC: 8624485. DOI: 10.3390/ijms222212371.

References

Zhang H, Zhou R, Li L, Chen J, Chen L, Li C . Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor. J Biol Chem. 2010; 286(3):1868-75. PMC: 3023482. DOI: 10.1074/jbc.M110.166215. View

Laffitte B, Chao L, Li J, Walczak R, Hummasti S, Joseph S . Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A. 2003; 100(9):5419-24. PMC: 154360. DOI: 10.1073/pnas.0830671100. View

Mangelsdorf D, Evans R . The RXR heterodimers and orphan receptors. Cell. 1995; 83(6):841-50. DOI: 10.1016/0092-8674(95)90200-7. View

Ogihara T, Chuang J, Vestermark G, Garmey J, Ketchum R, Huang X . Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling. J Biol Chem. 2009; 285(8):5392-404. PMC: 2820768. DOI: 10.1074/jbc.M109.064659. View

Nishimaki-Mogami T, Tamehiro N, Sato Y, Okuhira K, Sai K, Kagechika H . The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines. Biochem Pharmacol. 2008; 76(8):1006-13. DOI: 10.1016/j.bcp.2008.08.005. View

Kakuta H, Ohsawa F, Yamada S, Makishima M, Tai A, Yasui H . Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice. Biol Pharm Bull. 2012; 35(4):629-33. DOI: 10.1248/bpb.35.629. View

Fujii S, Ohsawa F, Yamada S, Shinozaki R, Fukai R, Makishima M . Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation. Bioorg Med Chem Lett. 2010; 20(17):5139-42. DOI: 10.1016/j.bmcl.2010.07.012. View

Ohsawa F, Morishita K, Yamada S, Makishima M, Kakuta H . Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers. ACS Med Chem Lett. 2014; 1(9):521-5. PMC: 4007838. DOI: 10.1021/ml100184k. View

Mukherjee R, Davies P, Crombie D, Bischoff E, Cesario R, Jow L . Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 1997; 386(6623):407-10. DOI: 10.1038/386407a0. View

10.

Takamatsu K, Takano A, Yakushiji N, Morohashi K, Morishita K, Matsuura N . The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist). ChemMedChem. 2008; 3(5):780-7. DOI: 10.1002/cmdc.200700313. View

11.

Miyazaki M, Dobrzyn A, Man W, Chu K, Sampath H, Kim H . Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms. J Biol Chem. 2004; 279(24):25164-71. DOI: 10.1074/jbc.M402781200. View

12.

Liu S, Ogilvie K, Klausing K, Lawson M, Jolley D, Li D . Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. Endocrinology. 2002; 143(8):2880-5. DOI: 10.1210/endo.143.8.8930. View

13.

Shulman A, Larson C, Mangelsdorf D, Ranganathan R . Structural determinants of allosteric ligand activation in RXR heterodimers. Cell. 2004; 116(3):417-29. DOI: 10.1016/s0092-8674(04)00119-9. View

14.

Lenhard J, Lancaster M, Paulik M, Weiel J, Binz J, Sundseth S . The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia. 1999; 42(5):545-54. DOI: 10.1007/s001250051193. View

15.

Mitro N, Mak P, Vargas L, Godio C, Hampton E, Molteni V . The nuclear receptor LXR is a glucose sensor. Nature. 2006; 445(7124):219-23. DOI: 10.1038/nature05449. View

16.

Li X, Hansen P, Xi L, Chandraratna R, Burant C . Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors. J Biol Chem. 2005; 280(46):38317-27. DOI: 10.1074/jbc.M505853200. View

17.

Kanda S, Nakashima R, Takahashi K, Tanaka J, Ogawa J, Ogata T . Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models. J Pharmacol Sci. 2009; 111(2):155-66. DOI: 10.1254/jphs.09084fp. View

18.

Davies P, Berry S, Shipley G, Eckel R, Hennuyer N, Crombie D . Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Mol Pharmacol. 2001; 59(2):170-6. DOI: 10.1124/mol.59.2.170. View

19.

de Lera A, Bourguet W, Altucci L, Gronemeyer H . Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov. 2007; 6(10):811-20. DOI: 10.1038/nrd2398. View

20.

Kim S, Kim H, Kim T, Im S, Park S, Lee I . SREBP-1c mediates the insulin-dependent hepatic glucokinase expression. J Biol Chem. 2004; 279(29):30823-9. DOI: 10.1074/jbc.M313223200. View